Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …

Multiple myeloma usually affects older adults. However, younger patients constitute a
significant subset as approximately 10% of cases occur in subjects younger than 50 years …

Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an
important therapy in the management of patients with multiple myeloma (MM), a disease of …

Melphalan at a dose of 200 mg/m 2 is standard conditioning prior to autologous
hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m 2 is …

Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma
(MM) for over three decades and is generally reserved for patients younger than 65. Herein …

High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) has historically
been an essential part of multiple myeloma (MM) management since early studies …

Background Repurposing existing medications for antineoplastic purposes can provide a
safe, cost-effective, and efficacious means to further augment available cancer care. Clinical …

Background Consolidative autologous hematopoietic stem cell transplantation (AHCT) is
commonly used for patients with multiple myeloma (MM). We studied AHCT use and …

Introduction In the literature there is lack of information on the influence of gender and time
since autologous hematopoietic stem cell transplantation (HSCT) on the immune …

The treatment of multiple myeloma has profoundly changed with the introduction of several
innovative therapies. The optimization of therapeutic sequencing through the combined use …